Storia in 2 fonti

Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival

Braveheart Bio files for a Nasdaq IPO to fund Phase 3 trials of heart drug BHB-1893, the fourth biotech IPO filing in two weeks.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo8 g fa

Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival

Braveheart Bio files for a Nasdaq IPO to fund Phase 3 trials of heart drug BHB-1893, the fourth biotech IPO filing in two weeks.

originale

biopharmadive.com9 g fa

Braveheart, Attovia join next wave of biotech IPOs

The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.

Leggi questa versione → originale

Timeline cronologica

mercoledì 15 luglio 2026·biopharmadive.com
Braveheart, Attovia join next wave of biotech IPOs
The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.
mercoledì 15 luglio 2026·endpoints.news
Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival
Braveheart Bio files for a Nasdaq IPO to fund Phase 3 trials of heart drug BHB-1893, the fourth biotech IPO filing in two weeks.